Ionis PDUFA and late-October earnings from ClearPoint, Merck, and Exelixis set the biotech agenda

The period is defined by one near-term FDA decision and a cluster of late-October earnings reports, with featured catalysts extending beyond the formal 2026-10-19..2026-10-25 window.¹²³⁴ For investors, that makes the setup less about broad sector tape and more about event-specific execution risk across IONS, CLPT, MRK, and EXEL.¹²³⁴

Ionis Pharmaceuticals is the cleanest binary on the slate, with a PDUFA date set for 2026-10-26, listed as in 8 days.¹ With no additional post, news, or wiki substrate attached here, the core issue is straightforward: IONS is approaching a regulatory decision that can reset the stock on approval, delay, or label-related nuance, and the event itself is the primary anchor for positioning.¹ Because the catalyst is an FDA action rather than a conference presentation or routine update, the market focus is likely to center on outcome clarity and immediate read-through rather than incremental narrative building.¹

ClearPoint Neuro reports earnings on 2026-10-28, in 10 days, and the surrounding substrate points back to the company’s exposure to procedure-enabling neurotechnology rather than a single binary product event.² The attached news flow spans MR-guided focused ultrasound in essential tremor, a locally administered tris-CAR-T study in newly diagnosed glioblastoma, and a simulation platform for deep brain stimulation, all of which reinforce the broader clinical and technical activity across neuromodulation and intracranial intervention settings that matter for CLPT’s operating backdrop.¹¹¹²¹³ That does not predetermine the quarter, but it does frame earnings as a check on whether management is converting participation in these neuro-interventional ecosystems into measurable commercial progress.^2111213

Merck reports earnings on 2026-10-29, in 11 days, with the richest surrounding substrate and a pre-computed KOL tally of 4 bullish, 0 bearish, and 1 neutral.³ The post set touches several pieces of the MRK story: one note links interest in a PAH candidate to the same drug class as Merck’s approved WINREVAIR, another flags ongoing unmet need in DME, and a third describes confident stage presence from Merck’s Dean Li alongside Moderna’s Stephen Hoge ahead of an ESMO presentation tied to the mRNA cancer vaccine effort.⁵⁸⁹ The lone neutral post is a market-wrap mention that includes MRK without advancing a directional thesis.⁷ News items also keep Merck connected to active oncology development through studies involving nivolumab and pembrolizumab-based combinations, which helps explain why earnings may be judged not only on quarterly numbers but also on how management updates the pipeline and strategic growth narrative.¹⁴¹⁵¹⁶ Taken together, the setup into the print is constructive in this dataset, with 4 bullish, 0 bearish, and 1 neutral, but the real test is whether results and guidance validate that optimism.^35789141516

Exelixis also reports earnings on 2026-10-29, in 11 days.⁴ The attached post substrate is limited but notable: one investor-survey summary cites EXEL among the least favorite SMID-cap biotech stocks, which introduces a skeptical element around current positioning even if no full tally is provided here.¹⁰ At the same time, the linked news item highlights a study of tegavivint plus zanzalintinib in advanced hepatocellular carcinoma, keeping attention on EXEL’s effort to extend value through pipeline development and combination strategies beyond its established commercial base.¹⁷ That leaves the earnings event as a two-part test of durability and expansion: whether the core business remains dependable and whether newer clinical programs are advancing convincingly enough to improve sentiment from here.⁴¹⁰¹⁷